Search Results - "Muskiet, M. H. A."

Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas by Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., van Raalte, D. H.

“…The gastrointestinal hormone glucagon‐like peptide‐1 (GLP‐1) lowers postprandial glucose concentrations by regulating pancreatic islet‐cell function, with…”
Get full text

Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men by Muskiet, M. H. A., Tonneijck, L., Smits, M. M., Kramer, M. H. H., Diamant, M., Joles, J. A., van Raalte, D. H.

“…Aims To determine the acute effect of glucagon‐like peptide‐1 (GLP‐1) receptor agonist exenatide and the involvement of nitric oxide (NO) on renal…”
Get full text

Ectopic Fat Storage in the Pancreas, Liver, and Abdominal Fat Depots: Impact on β-Cell Function in Individuals with Impaired Glucose Metabolism by van der Zijl, N. J, Goossens, G. H, Moors, C. C. M, van Raalte, D. H, Muskiet, M. H. A, Pouwels, P. J. W, Blaak, E. E, Diamant, M

“…Pancreatic fat content is increased in individuals with impaired glucose metabolism, without a direct relation on β-cell function. Context: Pancreatic fat…”
Get full text

Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial by Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Diamant, M., Pieters-van den Bos, I. C., van Raalte, D. H., Cahen, D. L.

“…Aims To investigate the effect of infusion of the glucagon‐like peptide‐1 (GLP‐1) receptor agonist exenatide on exocrine pancreatic function. Methods This was…”
Get full text

Saturated fat, carbohydrates and cardiovascular disease by KUIPERS, R. S, GRAAF, D. J. De, LUXWOLDA, M. F, MUSKIET, M. H. A, DIJCK-BROUWER, D. A. J, MUSKIET, F. A. J

“…The dietary intake of saturated fatty acids (SAFA) is associated with a modest increase in serum total cholesterol, but not with cardiovascular disease (CVD)…”
Get full text

Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial by Muskiet, M.H.A., Bunck, M.C., Heine, R.J., Cornér, A., Yki-Järvinen, H., Eliasson, B., Joles, J.A., Diamant, M., Tonneijck, L., van Raalte, D.H.

“…To compare the effects of long-term treatment with the GLP-1RA exenatide twice-daily versus titrated insulin glargine (iGlar) on renal function and albuminuria…”
Get full text

Acute plasma amylase increase after glucagon‐like peptide ‐1 receptor agonist exenatide administration in Type 2 diabetes by Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Diamant, M., Kramer, M. H. H., Cahen, D. L., Raalte, D. H.

Get full text

Influence of prednisolone on parameters of de novo lipogenesis and indices for stearoyl-CoA- and Δ6- desaturase activity in healthy males: A Post-hoc analysis of a randomized, placebo-controlled, double-blind trial by Pranger, I.G., van Raalte, D.H., Brands, M., Muskiet, M.H.A., Kema, I.P., Serlie, M.J., Diamant, M., Bakker, S.J.L., Muskiet, F.A.J.

“…•Glucocorticoids increase the DNL index and SCD index in plasma of healthy young males.•Glucocorticoids decrease the Δ-6 Desaturase index in plasma of healthy…”
Get full text